#China #Hangzhou #ESG #MSCI #Tigermed

Tigermed Achieves Renowned MSCI ESG AAA Rating

Tigermed, a leading global provider of integrated research and development solutions in the biopharmaceutical and medical device sectors, has proudly announced its receipt of the prestigious MSCI Environmental, Social, and Governance (ESG) Rating of AAA. This recognition is the highest in the industry and emphasizes Tigermed's dedication to exceptional ESG practices, positioning the firm as a frontrunner in sustainable business performance.

The rating of AAA is awarded to firms that demonstrate not only superior ESG performance but also resilience against long-term risks. For Tigermed, this accolade reflects its continuous dedication to embedding ESG principles into its core operations and strategic decision-making processes.

Commitment to Environmental Sustainability

Tigermed has established science-based targets aimed at reducing greenhouse gas emissions, all of which have been validated by the Science Based Targets initiative (SBTi). The company has taken significant steps by implementing a robust environmental management system that enhances its monitoring capabilities of emissions and resource utilization. Moreover, Tigermed has embraced digital platforms and initiated green office practices to foster environmental sustainability.

Advancements in Social Responsibility

In its endeavor to enhance the efficiency of clinical trials, Tigermed has actively advanced its digital transformation by leveraging cutting-edge AI technologies. In 2024 alone, the company made a considerable investment of approximately 39.997 million yuan in employee training initiatives, resulting in an impressive average of 99.48 training hours per employee. Tigermed prioritizes gender equality and promotes workforce diversity while also focusing on the well-being of its workforce. Through the Hangzhou Tigermed Foundation, the company engages in numerous public welfare activities, which include providing medical assistance, supporting education, and alleviating poverty. Notably, Tigermed has contributed to rural revitalization efforts, promoting consumption-based strategies for poverty reduction.

Strengthening Corporate Governance

In terms of governance, Tigermed has fortified its ESG governance and compliance framework. The oversight of ESG-related matters is entrusted to the board of directors, with direct management by a dedicated Compliance and ESG Committee that is led by the General Manager and supervised by the Chief Compliance Officer. Tigermed has also integrated ESG performance into the compensation structure of the General Manager, ensuring a commitment to these values at the leadership level. Furthermore, all employees benefit from comprehensive business ethics training, and new suppliers adhere to the Supplier Code of Conduct before commencing a business relationship, with regular assessments following.

Since first receiving its MSCI ESG rating in 2020, Tigermed has shown remarkable improvement in its rating, moving from an initial baseline to an AA rating in 2023, and has now proudly ascended to the coveted AAA rating. This development reflects the company's consistent investments in talent development, quality and safety management, carbon reduction strategies, and ethical business practices.

Looking Ahead

Achieving the AAA rating marks a significant milestone in Tigermed's ESG journey. The firm is set to enhance its ESG governance structure, refine its management systems, and promote sustainable growth in the future. As a company devoted to the motto "Serving Innovation, Building Health Together," Tigermed aims to create substantial long-term value for its stakeholders while contributing positively to global health and well-being.

About Tigermed

Tigermed, traded under stock codes 300347.SZ/3347.HK, is recognized as a premier global provider of integrated research and development solutions, specifically tailored for the biopharmaceutical and medical device industries. With a comprehensive service portfolio that spans from preclinical development through clinical trials to commercialization, Tigermed collaborates with over 3,600 customers, ensuring efficient and cost-effective development journeys. The company boasts a vast network of more than 180 locations and employs over 10,000 individuals across Asia Pacific, Europe, North America, Latin America, and Africa. Tigermed is dedicated to fostering an integrated platform that unlocks boundless possibilities for the healthcare sector, embracing challenges to fulfill unmet patient needs, and ultimately saving lives.

For more information, visit www.tigermedgrp.com.